Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 181

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Imaging Epidermal Growth Factor Receptor Expression In vivo : Pharmacokinetic and Biodistribution Characterization of a Bioconjugated Quantum Dot Nanoprobe

Open access
Diagaradjane, Parmeswaran, Orenstein-Cardona, Jacobo M., E. Colón-Casasnovas, Norman, Deorukhkar, Amit, Shentu, Shujun, Kuno, Norihito, Schwartz, David L., Gelovani, Juri G., Krishnan, Sunil·2008·Clinical Cancer Research

Abstract

Purpose: To develop and validate an optical imaging nanoprobe for the discrimination of epidermal growth factor (EGF) receptor (EGFR)–overexpressing tumors from surrounding normal tissues that also expresses EGFR. Experimental Design: Near-infrared (NIR) quantum dots (QD) were coupled to EGF using thiol-maleimide conjugation to create EGF-QD nanoprobes. In vitro binding affinity of these nanoprobes and unconjugated QDs was evaluated in a panel of cell lines, with and without anti-EGFR antibody pretreatment. Serial optical imaging of HCT116 xenograft tumors was done after systemic injection of QD and EGF-QD. Results: EGF-QD showed EGFR-specific binding in vitro. In vivo imaging showed three distinct phases, tumor influx (∼3 min), clearance (∼60 min), and accumulation (1-6 h), of EGF-QD nanoprobes. Both QD and EGF-QD showed comparable nonspecific rapid tumor influx and clearance followed by attainment of an apparent dynamic equilibrium at ∼60 min. Subsequently (1-6 h), whereas QD concentration gradually decreased in tumors, EGF-QDs progressively accumulated in tumors. On delayed imaging at 24 h, tumor fluorescence decreased to near-baseline levels for both QD and EGF-QD. Ex vivo whole-organ fluorescence, tissue homogenate fluorescence, and confocal microscopic analyses confirmed tumor-specific accumulation of EGF-QD at 4 h. Immunofluorescence images showed diffuse colocalization of EGF-QD fluorescence within EGFR-expressing tumor parenchyma compared with patchy perivascular sequestration of QD. Conclusion: These results represent the first pharmacokinetic characterization of a robust EGFR imaging nanoprobe. The measurable contrast enhancement of tumors 4 h after systemic administration of EGF-QD and its subsequent normalization at 24 h imply that this nanoprobe may permit quantifiable and repetitive imaging of EGFR expression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-07-1958

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 181

Metadata

Authors
Diagaradjane, P., Orenstein-Cardona, J. M., E. Colón-Casasnovas, N., Deorukhkar, A., Shentu, S., Kuno, N., Schwartz, D. L., Gelovani, J. G., & Krishnan, S.
Venue
Clinical Cancer Research
Published
2008-02-01
Volume
14
Issue
3
Pages
731-741
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2046415399
Cited by
181
References
2
FWCI
16.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Imaging Epidermal Growth Factor Receptor Expression In vivo : Pharmacokinetic and Biodistribution Characterization of a Bioconjugated Quantum Dot Nanoprobe. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-1958
The paper
Diagaradjane, P., Orenstein-Cardona, J. M., E. Colón-Casasnovas, N., Deorukhkar, A., Shentu, S., Kuno, N., Schwartz, D. L., Gelovani, J. G., & Krishnan, S. (2008). Imaging Epidermal Growth Factor Receptor Expression In vivo : Pharmacokinetic and Biodistribution Characterization of a Bioconjugated Quantum Dot Nanoprobe. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-1958

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.